Physician profile
Mark Y Kim
NPI 1487633228
$11,242.36
in general payments reported to CMS, 2019-2025
24 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $1,457 · 2021: $1,308 · 2022: $1,291 · 2023: $1,390 · 2024: $1,662 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,230.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,642.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,556.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,468.23 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,440.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $861.46 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $801.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $616.52 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $559.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $540.98 | 2019-2025 | |
| Exact Sciences Corporation | $411.84 | 2023-2025 | Cologuard Collection Kit |
| Tandem Diabetes Care, INC. | $225.00 | 2020 | |
| Grifols USA, LLC | $207.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $171.87 | 2019-2022 | |
| Daiichi Sankyo INC. | $161.37 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $154.83 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $118.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.79 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $67.39 | 2019-2022 | |
| Madrigal Pharmaceuticals | $38.06 | 2025 | Rezdiffra |
| Teva Pharmaceuticals USA, INC. | $28.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.88 | 2022 | |
| Amarin Pharma, INC. | $18.91 | 2023 | |
| Abbott Laboratories | $16.01 | 2022 | |
| Neotract INC. | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.